Jun 2026 (Q2 FY26) — Aug 5, 2026
Recursion Pharmaceuticals, Inc. Q2 FY26 — AI-Native Engine Drives Pipeline Progress and OpEx Efficiency
Read the full callRecursion Pharmaceuticals (RXRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Recursion Pharmaceuticals earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.7 | −60.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1759.7 | −842.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -131 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.61 +4.03% · +$0.14
Performance −38.4% 1Y
1Y: $5.86 on 17 Oct 2025 → $3.61. High $6.68 (20 Oct 2025), low $2.84 (30 Mar 2026).
- Previous close
- $3.47
- 52-week range
- $2.84 – $6.68
- One year
- −45.96%
Overview
- Symbol
- RXRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Recursion Pharmaceuticals earnings calls (RXRX)
Financials
What the filings say
Net profit, year on year: +24% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26 | 5 | 15 | 19 | 5 | 36 | 6 | 8 |
| Expenses | 124 | 188 | 206 | 195 | 177 | 144 | 135 | 143 |
| Operating profit | -98 | -184 | -191 | -176 | -172 | -108 | -129 | -135 |
| Operating margin | −377.1% | −4042.4% | −1297.8% | −916.8% | −3327.6% | −304.8% | −1985.5% | −1759.7% |
| Other income | 3 | 5 | -11 | 4 | 10 | 0 | 6 | 4 |
| Interest | 1 | 1 | 1 | 0 | 1 | -0 | 0 | 0 |
| Profit before tax | -96 | -179 | -203 | -172 | -162 | -108 | -122 | -131 |
| Tax rate | −0.2% | 0.0% | 0.1% | 0.0% | 0.0% | −0.0% | 3.8% | 0.0% |
| Net profit | -96 | -179 | -202 | -172 | -162 | -108 | -118 | -131 |
| EPS ($ per share) | -0.34 | — | -0.50 | -0.41 | -0.36 | — | -0.22 | -0.25 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -214 | -400 | -640 | -968 | -1,431 | -2,076 |
| Total liabilities | — | 57 | 67 | 215 | 190 | 414 | 343 |
| Fixed assets | — | 26 | 65 | 88 | 87 | 141 | 104 |
| Investments | — | 0 | 231 | 0 | — | — | — |
| Total assets | — | 299 | 610 | 701 | 654 | 1,449 | 1,474 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -57 | -45 | -159 | -84 | -288 | -359 | -372 |
| Cash from investing | -4 | -9 | -272 | 193 | -10 | 260 | -17 |
| Cash from financing | 120 | 246 | 459 | 154 | 140 | 304 | 522 |
| Net cash flow | 59 | 192 | 28 | 264 | -158 | 202 | 151 |
| Capital expenditure | -4 | -6 | -40 | -37 | -12 | -14 | -6 |
| Free cash flow | -61 | -51 | -198 | -121 | -300 | -373 | -378 |
Insider filings
105 filings between Oct 23, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.22M
36 sales by 6 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 23
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
- 24
- Tax withheld — shares kept back by the company to cover tax
Also filed: 16 conversions, 5 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Borgeson Blake | — | $4.34M | Oct 6, 2026 |
| Gibson Christopher | — | $2.76M | Jun 5, 2026 |
| Khan Najat | — | $806.5K | Sep 8, 2026 |
| Taylor Ben R | — | $157.7K | Mar 17, 2026 |
| HERSHBERG ROBERT | — | $125.0K | Oct 6, 2026 |
| Bumpus Namandje | — | $28.1K | Jun 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | HERSHBERG ROBERT Director | Option exercise 10b5-1 plan | 25,000 | $55.5K |
| Oct 6, 2026 | HERSHBERG ROBERT Director | Sale 10b5-1 plan | 25,000 | $125.0K |
| Oct 6, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 50,000 | $242.0K |
| Oct 1, 2026 | Dar Zavain Director | Award | 4,607 | $0 |
| Oct 1, 2026 | Li Dean Y Director | Award | 3,378 | $0 |
| Sep 15, 2026 | Taylor Ben R Chief Financial Officer | Tax withheld | 5,396 | $18.4K |
| Sep 8, 2026 | Khan Najat CEO and President | Sale 10b5-1 plan | 22,408 | $78.8K |
| Sep 1, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 30,000 | $100.2K |
| Aug 17, 2026 | Khan Najat CEO and President | Tax withheld | 80,498 | $254.4K |
| Aug 17, 2026 | Taylor Ben R Chief Financial Officer | Tax withheld | 25,018 | $79.1K |
| Aug 17, 2026 | Hallett David Chief Scientific Officer | Tax withheld | 26,657 | $84.2K |
| Aug 4, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 30,000 | $97.5K |
| Jul 7, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 40,000 | $158.5K |
| Jul 1, 2026 | Dar Zavain Director | Award | 5,109 | $0 |
| Jul 1, 2026 | Li Dean Y Director | Award | 3,747 | $0 |
| Jun 18, 2026 | Bumpus Namandje Director | Sale 10b5-1 plan | 3,963 | $12.6K |
| Jun 17, 2026 | Borgeson Blake Director | Award | 88,424 | $0 |
| Jun 17, 2026 | HERSHBERG ROBERT Director | Award | 88,424 | $0 |
| Jun 17, 2026 | Michor Franziska Director | Award | 88,424 | $0 |
| Jun 17, 2026 | Sun Elaine D Director | Award | 88,424 | $0 |
| Jun 17, 2026 | Dar Zavain Director | Award | 88,424 | $0 |
| Jun 17, 2026 | Bumpus Namandje Director | Award 10b5-1 plan | 88,424 | $0 |
| Jun 17, 2026 | Li Dean Y Director | Award | 88,424 | $0 |
| Jun 15, 2026 | Taylor Ben R Chief Financial Officer | Tax withheld | 5,396 | $17.0K |
| Jun 5, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 40,000 | $0 |
| Jun 5, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $144.8K |
| Jun 5, 2026 | Khan Najat CEO and President | Sale 10b5-1 plan | 23,588 | $84.5K |
| Jun 3, 2026 | Bumpus Namandje Director | Sale 10b5-1 plan | 4,386 | $15.5K |
| Jun 2, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 30,000 | $110.4K |
| May 22, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 40,000 | $0 |
| May 22, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $123.2K |
| May 15, 2026 | Taylor Ben R Chief Financial Officer | Tax withheld | 25,018 | $76.1K |
| May 15, 2026 | Gibson Christopher Director | Tax withheld | 22,821 | $69.4K |
| May 15, 2026 | Khan Najat CEO and President | Tax withheld | 62,701 | $190.6K |
| May 15, 2026 | Hallett David Chief Scientific Officer | Tax withheld | 26,657 | $81.0K |
| May 7, 2026 | Gibson Christopher Director | Gift 10b5-1 plan | 20,000 | $0 |
| May 7, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $134.8K |
| May 7, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 60,000 | $0 |
| May 5, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 30,000 | $105.6K |
| Apr 22, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 40,000 | $0 |
| Apr 22, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $144.4K |
| Apr 7, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $124.0K |
| Apr 7, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 40,000 | $0 |
| Apr 7, 2026 | Borgeson Blake Director | Sale 10b5-1 plan | 30,000 | $93.0K |
| Apr 6, 2026 | Taylor Ben R Chief Financial Officer | Tax withheld | 48,028 | $149.4K |
| Apr 1, 2026 | Dar Zavain Director | Award | 4,902 | $0 |
| Apr 1, 2026 | Li Dean Y Director | Award | 3,268 | $0 |
| Mar 23, 2026 | Gibson Christopher Director | Conversion 10b5-1 plan | 40,000 | $0 |
| Mar 23, 2026 | Gibson Christopher Director | Sale 10b5-1 plan | 40,000 | $130.0K |
| Mar 17, 2026 | Taylor Ben R Chief Financial Officer | Sale 10b5-1 plan | 7,956 | $27.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for RECURSION PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow RECURSION PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading